Subject Enrollment Sample Clauses

Subject Enrollment. The Principal Investigator shall enroll subjects into the Study in accordance with the applicable SOW and the applicable Protocol (each a “Subject”). The Principal Investigator shall use all reasonable efforts to complete enrollment prior to any Subject Enrollment Closing Date set forth in writing to the Principal Investigator by SPONSOR. The Study period and the number of Subjects the Institution may enroll in the Study may be extended or shortened at SPONSOR’s sole discretion. The Institution acknowledges and agrees that if a Study is part of a study taking place at multiple sites (a “Multi-Center Study”), that when the enrollment goal for such Multi-Center Study as a whole is reached, enrollment will be closed at all sites, including the Institution, regardless of whether the Institution or any other site has reached its individual enrollment goal.

Subject Enrollment. Institution shall ensure that Principal Investigator shall only enroll Subjects that meet the applicable Protocol requirements. Institution shall ensure that Principal Investigator shall exercise independent medical judgment as to the compatibility of each Subject with the Protocol requirements.

Subject Enrollment. The Institution and the Principal Investigator have agreed to enroll qualified Study participants during the Sponsor-specified enrollment period, unless the Sponsor modifies the enrollment period by written notice. A qualified participant is one who meets all Protocol criteria for inclusion in the Study ("Study Subject").

Subject Enrollment. The Institution and the Principal Investigator have agreed to endeavor to enroll in the Study an estimated quantity of but not more than qualified Study participants by , unless the Sponsor, upon the Sponsor’s prior instructions, modifies this enrollment period by written notice. A qualified participant is one who meets all Protocol criteria for inclusion in the Study (hereinafter, a “Study Subject”). [Revise if only a minimum or only a maximum number will be specified but not both]

Subject Enrollment. Principal Investigator has agreed to enroll qualified Study participants during the CRO-specified enrollment period, unless CRO modifies the enrollment period by written notice. A qualified participant is one who meets all Protocol criteria for inclusion in the Study (“Study Subject”).

Subject Enrollment. Principal Investigator will enroll in the Study a minimum of but no more than qualified subjects by Mmm dd, yyyy, unless Sponsor extends this enrollment period by written notification. A qualified subject is one who meets all Protocol criteria for inclusion in the Study.

Subject Enrollment. Institution has agreed through Principal Investigator to enroll qualified Study participants during the Pfizer-specified enrollment period, unless CRO, upon Pfizer’s prior 4. Zařazení subjektů. Instituce souhlasí s tím, že v průběhu doby stanovené společností Pfizer zařadí prostřednictvím Hlavního zkoušejícího do Studie způsobilé účastníky Studie, ledaže CRO na instructions, modifies the enrollment period by written notice. A qualified participant is one who meets all Protocol criteria for inclusion in the Study (“Study Subject”). základě předchozích pokynů společnosti Pfizer změní období zařazování písemným oznámením. Způsobilý účastník je osoba, která splňuje všechna kritéria Protokolu pro zařazení do Studie (dále jen „Subjekt Studie“).

Subject Enrollment. Institution agrees use reasonable efforts to enroll in Study a minimum of but no more than Study Subjects by , unless CRO modifies this enrollment period by written notice. However, the Parties understand and acknowledge that enrollment numbers are subject to the individuals patients’ best interest and/or willingness to participate, and therefore cannot be guaranteed. As used in this Study Order, “Study Subject” means a participant who is both enrolled in the Study and has met all the Protocol criteria for full participation.

Subject Enrollment. The Study will begin on or about November 27, 2014 at the Study Facility(ies) identified in the initial FDA Form 1572 for the Study; provided, however, (i) that IRB approval of (a) the Protocol, (b) the informed consent form and HIPAA Authorization (as defined in Section 6.1), and (c) any advertisements or public solicitations for enrollment have been obtained in accordance with Sections 2.2 and 6.3, (ii) each Party has received a copy of the fully executed Agreement and (iii) USOR has delivered, on behalf of itself and Sites, all applicable regulatory documents to BIND. USOR shall not conduct the Study at any other location without the prior written consent of BIND. The maximum planned enrollment for the Study is nineteen (19)